MimiVax Announces Data Cutoff for Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma
MimiVax Announces Data Cutoff for Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma
BUFFALO, N.Y., July 15, 2026 — MimiVax Inc., a clinical-stage biotechnology company dedicated to the development of innovative cancer immunotherapies, today announced that data cutoff has been reached for the SURVIVE trial…